Search

Your search keyword '"Molina, Lysiane"' showing total 49 results
Start Over Author "Molina, Lysiane"
49 results on '"Molina, Lysiane"'

1. Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial

Author

Guièze, Romain, Ysebaert, Loïc, Roos-Weil, Damien, Fornecker, Luc-Mathieu, Ferrant, Emmanuelle, Molina, Lysiane, Aurran, Thérèse, Clavert, Aline, de Guibert, Sophie, Michallet, Anne-Sophie, Saad, Alain, Drénou, Bernard, Quittet, Philippe, Hivert, Bénédicte, Laribi, Kamel, Gay, Julie, Quinquenel, Anne, Broseus, Julien, Rouille, Valérie, Schwartz, David, Magnin, Benoit, Lazarian, Grégory, Véronèse, Lauren, de Antonio, Marie, Laurent, Camille, Tournilhac, Olivier, Pereira, Bruno, and Feugier, Pierre

Published
2024
Full Text
View/download PDF

2. Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines

Author

Rossi, Cédric, Manson, Guillaume, Marouf, Amira, Cabannes-Hamy, Aurélie, Nicolas-Virelizier, Emmanuelle, Maerevoet, Marie, Alcantara, Marion, Molina, Lysiane, Ceraulo, Antony, Poirée, Marilyne, Galtier, Jean, Diop, Nadia, Delette, Caroline, Segot, Amandine, Dubois, Sydney, Waultier, Agathe, Bernard, Sophie, Noël, Robin, Guidez, Stéphanie, Kohn, Milena, Bailly, Sébastien, Moatti, Hannah, Touati, Mohamed, Renaud, Loïc, Kanoun, Salim, Cottereau, Anne-Ségolène, Kirova, Youlia, Peignaux, Karine, Dourthe, Marie-Emilie, Simonin, Mathieu, Leblanc, Thierry, Quéro, Laurent, Krzisch, Daphné, Duléry, Remy, Grenier, Adrien, Gastinne, Thomas, Casasnovas, Olivier, Gallamini, Andrea, André, Marc, Morschhauser, Franck, Deau, Bénédicte, Fornecker, Luc-Mathieu, and Ghesquières, Hervé

Published
2024
Full Text
View/download PDF

3. A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Author

Michallet, Anne-Sophie, Letestu, Rémi, Le Garff-Tavernier, Magali, Campos, Lydia, Ticchioni, Michel, Dilhuydy, Marie-Sarah, Morisset, Stephane, Rouille, Valérie, Mahé, Béatrice, Laribi, Kamel, Villemagne, Bruno, Ferrant, Emmanuelle, Tournilhac, Olivier, Delmer, Alain, Molina, Lysiane, Leblond, Véronique, Tomowiak, Cécile, de Guibert, Sophie, Orsini-Piocelle, Frederique, Banos, Anne, Carassou, Philippe, Cartron, Guillaume, Fornecker, Luc Mathieu, Ysebaert, Loic, Dartigeas, Caroline, Truchan-Graczyk, Margot, Vilque, Jean-Pierre, Schleinitz, Thérèse Aurran, Cymbalista, Florence, Leprêtre, Stéphane, Lévy, Vincent, Nguyen-Khac, Florence, and Feugier, Pierre

Published
2023
Full Text
View/download PDF

4. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Author

Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Published
2022
Full Text
View/download PDF

7. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Author

Houot, Roch, Cartron, Guillaume, Bijou, Fontanet, de Guibert, Sophie, Salles, Gilles A., Fruchart, Christophe, Bouabdallah, Krimo, Maerevoet, Marie, Feugier, Pierre, Le Gouill, Steven, Tilly, Hervé, Casasnovas, Rene-Olivier, Moluçon-Chabrot, Cécile, Van Den Neste, Eric, Zachee, Pierre, Andre, Marc, Bonnet, Christophe, Haioun, Corinne, Van Hoof, Achiel, Van Eygen, Koen, Molina, Lysiane, Nicolas-Virelizier, Emmanuelle, Ruminy, Philippe, and Morschhauser, Franck

Published
2019
Full Text
View/download PDF

8. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH)

Author

Fornecker, Luc-Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René-Olivier, Gac, Anne-Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, André, Marc, LYSA-FIL-EORTC Intergroup, Hematology, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
Adult, Brentuximab Vedotin, Cancer Research, Adolescent, Middle Aged, Vinblastine, Hodgkin Disease, Dacarbazine, Hodgkin lymphoma, brentuximab vedotin, Young Adult, Bleomycin, Treatment Outcome, Oncology, SDG 3 - Good Health and Well-being, Doxorubicin, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasm Staging
Abstract

PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979 ). METHODS BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD. RESULTS Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively. CONCLUSION BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

Published
2023

9. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH):A Multicenter, Open-Label, Randomized, Phase II Trial

Author

Fornecker, Luc Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René Olivier, Gac, Anne Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, André, Marc, Fornecker, Luc Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René Olivier, Gac, Anne Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, and André, Marc

Abstract

PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979). METHODS BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD. RESULTS Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively. CONCLUSION BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles., PURPOSEThe prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979).METHODSBREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD.RESULTSBetween March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P <.001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively.CONCLUSIONBV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

Published
2023

11. Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Author

Aurran-Schleinitz, Therese, primary, Tomowiak, Cécile, additional, Roos-Weil, Damien, additional, Ferrant, Emmanuelle, additional, Mahé, Béatrice, additional, Molina, Lysiane, additional, Ysebaert, Loic, additional, Fornecker, Luc Mathieu, additional, Michallet, Anne-Sophie, additional, Levy, Vincent, additional, Guieze, Romain, additional, and Delmer, Alain, additional

Published
2022
Full Text
View/download PDF

12. A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Author

Michallet, Anne-Sophie, primary, Letestu, Rémi, additional, Le Garff-Tavernier, Magali, additional, Aanaei, Carmen, additional, Ticchioni, Michel, additional, Dilhuydy, Marie-Sarah, additional, Morisset, Stephane, additional, Rouille, Valérie, additional, Mahé, Béatrice, additional, Laribi, Kamel, additional, Villemagne, Bruno, additional, Ferrant, Emmanuelle, additional, Tournilhac, Olivier, additional, Delmer, Alain, additional, Portois, Christelle, additional, Molina, Lysiane, additional, Leblond, Véronique, additional, Tomowiak, Cécile, additional, de Guibert, Sophie, additional, Orsini, Frederique, additional, Banos, Anne, additional, Carassou, Philippe, additional, Cartron, Guillaume, additional, Fornecker, Luc Mathieu, additional, Ysebaert, Loic, additional, Dartigeas, Caroline, additional, Truchan, Margot, additional, Vilque, Jean-Pierre, additional, Aurran Schleinitz, Therese, additional, Florence, Cymbalista, additional, Leprêtre, Stéphane, additional, Lévy, Vincent, additional, Nguyen Khac, Florence, additional, and Feugier, Pierre, additional

Published
2022
Full Text
View/download PDF

13. Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Author

Guieze, Romain, primary, Ysebaert, Loic, additional, Roos-Weil, Damien, additional, Fornecker, Luc-Matthieu, additional, Ferrant, Emmanuelle, additional, Molina, Lysiane, additional, Aurran-Schleinitz, Thérèse, additional, Clavert, Aline, additional, de Guibert, Sophie, additional, Michallet, Anne-Sophie, additional, Saad, Alain, additional, Drenou, Bernard, additional, Quittet, Philippe, additional, Hivert, Benedicte, additional, Laribi, Kamel, additional, Gay, Julie, additional, Broséus, Julien, additional, Rouille, Valérie, additional, Schwartz, David, additional, Pereira, Bruno, additional, Delmer, Alain, additional, and Feugier, Pierre, additional

Published
2022
Full Text
View/download PDF

14. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Author

Quinquenel, Anne, primary, Letestu, Rémi, additional, Le Garff-Tavernier, Magali, additional, Subtil, Fabien, additional, Aurran-Schleinitz, Therese, additional, Laribi, Kamel, additional, Cymbalista, Florence, additional, Levy, Vincent, additional, Simon, Laurence, additional, Roos-Weil, Damien, additional, Leblond, Véronique, additional, Dilhuydy, Marie-Sarah, additional, Dartigeas, Caroline, additional, Tomowiak, Cecile, additional, Guieze, Romain, additional, Tournilhac, Olivier, additional, Ferrant, Emmanuelle, additional, de Guibert, Sophie, additional, Feugier, Pierre, additional, Merabet, Fatiha, additional, Lepretre, Stephane, additional, Carassou, Philippe, additional, Gay, Julie, additional, Hivert, Bénédicte, additional, Fornecker, Luc Mathieu, additional, Dupuis, Jehan, additional, Molina, Lysiane, additional, Villemagne, Bruno, additional, Cartron, Guillaume, additional, Drenou, Bernard, additional, Mahé, Béatrice, additional, Benbrahim, Omar, additional, Cahu, Xavier, additional, Portois, Christelle, additional, Ysebaert, Loic, additional, Nguyen Khac, Florence, additional, Rouille, Valérie, additional, Delmer, Alain, additional, and Michallet, Anne-Sophie, additional

Published
2022
Full Text
View/download PDF

15. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, Morschhauser, Franck, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Abstract

Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.

Published
2022

16. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Fornecker, Luc-Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René-Olivier, Gac, Anne-Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, André, Marc, LYSA-FIL-EORTC Intergroup, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Fornecker, Luc-Matthieu, Lazarovici, Julien, Aurer, Igor, Casasnovas, René-Olivier, Gac, Anne-Claire, Bonnet, Christophe, Bouabdallah, Krimo, Feugier, Pierre, Specht, Lena, Molina, Lysiane, Touati, Mohamed, Borel, Cécile, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Pascal, Laurent, Lugtenburg, Pieternella, Di Renzo, Nicola, Vander Borght, Thierry, Traverse-Glehen, Alexandra, Dartigues, Peggy, Hutchings, Martin, Versari, Annibale, Meignan, Michel, Federico, Massimo, André, Marc, and LYSA-FIL-EORTC Intergroup

Abstract

The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979). BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD. Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively. BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

Published
2022

17. Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Author

Guieze, Romain, primary, Ysebaert, Loic, additional, Roos-Weil, Damien, additional, Molina, Lysiane, additional, Fornecker, Luc Mathieu, additional, Aurran, Thérèse, additional, Michallet, Anne-Sophie, additional, Ferrant, Emmanuelle, additional, Clavert, Aline, additional, Saad, Alain, additional, de Guibert, Sophie, additional, Drenou, Bernard, additional, Quittet, Philippe, additional, Hivert, Bénédicte, additional, Laribi, Kamel, additional, Gay, Julie, additional, Broséus, Julien, additional, Rouille, Valérie, additional, Schwartz, David, additional, Pereira, Bruno, additional, Delmer, Alain, additional, and Feugier, Pierre, additional

Published
2021
Full Text
View/download PDF

18. Nivolumab First-Line Therapy for Elderly, Frail Hodgkin Lymphoma Patients: Niviniho, a Lysa Phase II Study

Author

Lazarovici, Julien, primary, Amorim, Sandy, additional, Bouabdallah, Krimo, additional, Guidez, Stéphanie, additional, Molina, Lysiane, additional, Morschhauser, Franck, additional, Gac, Anne-Claire, additional, Gastinne, Thomas, additional, Laribi, Kamel, additional, Launay, Vincent, additional, Slama, Bohrane, additional, Belmecheri, Nawel, additional, Casasnovas, René-Olivier, additional, Corby, Anne, additional, Durot, Eric, additional, Feugier, Pierre, additional, Nicolas-Virelizier, Emmanuelle, additional, Sibon, David, additional, Berriolo-Riedinger, Alina, additional, Edeline, Veronique, additional, Vander Borght, Thierry, additional, Damotte, Diane, additional, Traverse-Glehen, Alexandra, additional, Andre, Marc, additional, and Ribrag, Vincent, additional

Published
2021
Full Text
View/download PDF

19. Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Author

Michallet, Anne-Sophie, primary, Quinquenel, Anne, additional, Letestu, Remi, additional, Le Garff-Tavernier, Magali, additional, Subtil, Fabien, additional, Elsensohn, Mad-Helenie, additional, Aurran, Therese, additional, Laribi, Kamel, additional, Cymbalista, Florence, additional, Levy, Vincent, additional, Simon, Laurence, additional, Roos-Weil, Damien, additional, Leblond, Veronique, additional, Dilhuydy, Marie-Sarah, additional, Tomowiak, Cécile, additional, Dartigeas, Caroline, additional, Guieze, Romain, additional, Tournilhac, Olivier, additional, Ferrant, Emmanuelle, additional, de Guibert, Sophie, additional, Feugier, Pierre, additional, Merabet, Fatiha, additional, Leprêtre, Stéphane, additional, Carassou, Philippe, additional, Gay, Julie, additional, Hivert, Bénédicte, additional, Fornecker, Luc Mathieu, additional, Dupuis, Jehan, additional, Molina, Lysiane, additional, Villemagne, Bruno, additional, Cartron, Guillaume, additional, Drenou, Bernard, additional, Mahé, Béatrice, additional, Benbrahim, Omar, additional, Cahu, Xavier, additional, Portois, Christelle, additional, Ysebaert, Loic, additional, Nguyen-Khac, Florence, additional, Rouille, Valérie, additional, and Delmer, Alain, additional

Published
2021
Full Text
View/download PDF

21. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization ( FILO )

Author

Lazarian, Grégory, primary, Munger, Michaël, additional, Quinquenel, Anne, additional, Dilhuydy, Marie‐Sarah, additional, Veronese, Lauren, additional, Luque Paz, Damien, additional, Guièze, Romain, additional, Ledoux‐Pilon, Albane, additional, Paillassa, Jérôme, additional, Merabet, Fatiha, additional, Vial, Jean‐Philippe, additional, Bidet, Audrey, additional, Waultier Rascalou, Agathe, additional, Broseus, Julien, additional, Roos‐Weil, Damien, additional, Lavaud, Anne, additional, Molina, Lysiane, additional, Laribi, Kamel, additional, Hivert, Bénédicte, additional, Friedrich, Chloé, additional, Carpentier, Benjamin, additional, Ysebaert, Loïc, additional, Van Den Neste, Eric, additional, Willems, Lise, additional, Corby, Anne, additional, Poulain, Stéphanie, additional, Eclache, Virginie, additional, Maubec, Eve, additional, Martin, Antoine, additional, Feugier, Pierre, additional, Delmer, Alain, additional, Baran‐Marszak, Fanny, additional, Leprêtre, Stéphane, additional, and Cymbalista, Florence, additional

Published
2021
Full Text
View/download PDF

22. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).

Author

UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Lazarian, Grégory, Munger, Michaël, Quinquenel, Anne, Dilhuydy, Marie-Sarah, Veronese, Lauren, Luque Paz, Damien, Guièze, Romain, Ledoux-Pilon, Albane, Paillassa, Jérôme, Merabet, Fatiha, Vial, Jean-Philippe, Bidet, Audrey, Waultier Rascalou, Agathe, Broseus, Julien, Roos-Weil, Damien, Lavaud, Anne, Molina, Lysiane, Laribi, Kamel, Hivert, Bénédicte, Friedrich, Chloé, Carpentier, Benjamin, Ysebaert, Loïc, Van Den Neste, Eric, Willems, Lise, Corby, Anne, Poulain, Stéphanie, Eclache, Virginie, Maubec, Eve, Martin, Antoine, Feugier, Pierre, Delmer, Alain, Baran-Marszak, Fanny, Leprêtre, Stéphane, Cymbalista, Florence, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Lazarian, Grégory, Munger, Michaël, Quinquenel, Anne, Dilhuydy, Marie-Sarah, Veronese, Lauren, Luque Paz, Damien, Guièze, Romain, Ledoux-Pilon, Albane, Paillassa, Jérôme, Merabet, Fatiha, Vial, Jean-Philippe, Bidet, Audrey, Waultier Rascalou, Agathe, Broseus, Julien, Roos-Weil, Damien, Lavaud, Anne, Molina, Lysiane, Laribi, Kamel, Hivert, Bénédicte, Friedrich, Chloé, Carpentier, Benjamin, Ysebaert, Loïc, Van Den Neste, Eric, Willems, Lise, Corby, Anne, Poulain, Stéphanie, Eclache, Virginie, Maubec, Eve, Martin, Antoine, Feugier, Pierre, Delmer, Alain, Baran-Marszak, Fanny, Leprêtre, Stéphane, and Cymbalista, Florence

Abstract

TO THE EDITOR : Patients with chronic lymphocytic leukemia (CLL) exhibit a variety of skin lesions including mostly non-specific cutaneous manifestations (such as cutaneous infections or exaggerated reactions to insect bite) and secondary cutaneous malignancies, as patients are at high risk of developing basal cell carcinoma, squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Specific cutaneous infiltration by neoplastic B lymphocytes with clinically identifiable skin lesions, also called leukemia cutis (LC), is more uncommon and has seldom been reported in chronic lymphocytic leukemia. [...]

Published
2021

23. Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Author

Michallet, Anne-Sophie, Quinquenel, Anne, Letestu, Remi, Magali, Tavernier, Morisset, Stéphane, Aurran, Therese, Laribi, Kamel, Cymbalista, Florence, Levy, Vincent, Simon, Laurence, Roos Weil, Damien, Leblond, Veronique, Dilhuydy, Marie Sarah, Tomowiak, Cecile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, De Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Lepretre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Benedicte, Fornecker, Luc Matthieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Mahé, Béatrice, Benbrahim, Omar, Cahu, Xavier, Portois, Christelle, Ysebaert, Loic, Nguyen Khac, Florence, Rouillé, Valerie, and Delmer, Alain Jacques

Published
2023
Full Text
View/download PDF

24. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
0301 basic medicine, Male, Cancer Research, Neoplasm, Residual, MESH: Immunotherapy, Chronic lymphocytic leukemia, Gastroenterology, MESH: Clinical Trials, Phase III as Topic, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Aged, education.field_of_study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Prognosis, 3. Good health, Fludarabine, Survival Rate, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Vidarabine, MESH: Bone Marrow, Female, MESH: Rituximab, Immunotherapy, Rituximab, MESH: Clinical Trials, Phase II as Topic, Vidarabine, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Chemoimmunotherapy, Internal medicine, medicine, Humans, education, Survival rate, MESH: Neoplasm, Residual, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Retrospective Studies, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Male, body regions, 030104 developmental biology, Clinical Trials, Phase III as Topic, Bone marrow, business, MESH: Female, Follow-Up Studies
Abstract

International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD

Published
2020
Full Text
View/download PDF

25. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study

Author

Hutchings, Martin, primary, Radford, John, additional, Ansell, Stephen M., additional, Illés, Árpád, additional, Sureda, Anna, additional, Connors, Joseph M., additional, Sýkorová, Alice, additional, Shibayama, Hirohiko, additional, Abramson, Jeremy S., additional, Chua, Neil S., additional, Friedberg, Jonathan W., additional, Kořen, Jan, additional, LaCasce, Ann Steward, additional, Molina, Lysiane, additional, Engley, Gerald, additional, Fenton, Keenan, additional, Jolin, Hina, additional, Liu, Rachael, additional, Gautam, Ashish, additional, and Gallamini, Andrea, additional

Published
2021
Full Text
View/download PDF

27. Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Author

Guieze, Romain, primary, Ysebaert, Loic, additional, Molina, Lysiane, additional, Roos-Weil, Damien, additional, Michallet, Anne-Sophie, additional, Hivert, Benedicte, additional, Gay, Julie, additional, Saad, Alain, additional, Fornecker, Luc Mathieu, additional, Broséus, Julien, additional, Rouille, Valérie, additional, Auvray, Laëtitia, additional, Delmer, Alain Jacques, additional, and Feugier, Pierre, additional

Published
2020
Full Text
View/download PDF

28. Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience

Author

Jourdan, Eric, Boiron, Jean-Michel, Dastugue, Nicole, Vey, Norbert, Marit, Gérald, Rigal-Huguet, Françoise, Molina, Lysiane, Fegueux, Nathalie, Pigneux, Arnaud, Recher, Christian, Rossi, Jean-François, Attal, Michel, Sotto, Jean-Jacques, Maraninchi, Dominique, Reiffers, Josy, Bardou, Valerie-Jeanne, Esterni, Benjamin, and Blaise, Didier

Published
2005
Full Text
View/download PDF

30. De novo adult acute myeloid leukemia patients’ display at diagnosis functional deregulation of redox balance correlated with molecular subtypes and overall survival

Author

Mondet, Julie, primary, Presti, Caroline Lo, additional, Garrel, Catherine, additional, Skaare, Kristina, additional, Mariette, Clara, additional, Carras, Sylvain, additional, Park, Sophie, additional, Carré, Martin, additional, Bulabois, Claude-Eric, additional, Molina, Lysiane, additional, Gressin, Rémy, additional, Thiebaut, Anne, additional, Courby, Stéphane, additional, Socoro-Yuste, Nuria, additional, Faure, Patrice, additional, Leer, Anne Mc, additional, Cahn, Jean-Yves, additional, and Mossuz, Pascal, additional

Published
2019
Full Text
View/download PDF

31. Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival

Author

Mondet, Julie, primary, Presti, Caroline Lo, additional, Garrel, Catherine, additional, Skaare, Kristina, additional, Mariette, Clara, additional, Carras, Sylvain, additional, Park, Sophie, additional, Carré, Martin, additional, Bulabois, Claude-Eric, additional, Molina, Lysiane, additional, Gressin, Rémy, additional, Thiebaut, Anne, additional, Courby, Stéphane, additional, Socoro-Yuste, Nuria, additional, Faure, Patrice, additional, Leer-Florin, Anne Mc, additional, Cahn, Jean-Yves, additional, and Mossuz, Pascal, additional

Published
2019
Full Text
View/download PDF

32. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Houot, Roch, Cartron, Guillaume, Bijou, Fontanet, de Guibert, Sophie, Salles, Gilles A, Fruchart, Christophe, Bouabdallah, Krimo, Maerevoet, Marie, Feugier, Pierre, Le Gouill, Steven, Tilly, Hervé, Casasnovas, Rene-Olivier, Moluçon-Chabrot, Cécile, Van Den Neste, Eric, Zachee, Pierre, André, Marc, Bonnet, Christophe, Haioun, Corinne, Van Hoof, Achiel, Van Eygen, Koen, Molina, Lysiane, Nicolas-Virelizier, Emmanuelle, Ruminy, Philippe, Morschhauser, Franck, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Houot, Roch, Cartron, Guillaume, Bijou, Fontanet, de Guibert, Sophie, Salles, Gilles A, Fruchart, Christophe, Bouabdallah, Krimo, Maerevoet, Marie, Feugier, Pierre, Le Gouill, Steven, Tilly, Hervé, Casasnovas, Rene-Olivier, Moluçon-Chabrot, Cécile, Van Den Neste, Eric, Zachee, Pierre, André, Marc, Bonnet, Christophe, Haioun, Corinne, Van Hoof, Achiel, Van Eygen, Koen, Molina, Lysiane, Nicolas-Virelizier, Emmanuelle, Ruminy, Philippe, and Morschhauser, Franck

Published
2018

33. A review of 76 patients with myelodysplastic syndromes treated with danazol

Author

Chabannon, Christian, Molina, Lysiane, Pegourie-Bandelier, Brigitte, Bost, Mireille, Leger, Jacqueline, and Hollard, Daniel

Subjects
Myelodysplastic syndromes, Danazol -- Physiological aspects, Health
Abstract

Background. Treatment of myelodysplastic syndromes (MDSs) remains unsatisfactory. A limited number of reports provide contradictory information on whether danazol, a synthetic androgen, may be useful in patients with MDS. Methods. Between 1984 and 1992, 76 patients were treated with danazol (Danatrol, Winthrop) in an open nonrandomized study. Clinical status, blood counts, differential marrow cell counts, transfusion requirements, and liver enzymes were monitored at 3-month intervals during and 6 months after discontinuation of therapy. The authors present the retrospective analysis of this cohort of patients. Results. This study shows a limited usefulness of danazol in patients with MDS. Blood counts were not significantly changed during danazol administration; neither were transfusion requirements. Overall survival and the rate of leukemic transformation were not affected when compared with 50 untreated patients or with data available in the literature. An increase in platelet numbers in four patients and in hemoglobin level in one patient was observed; these patients were unremarkable and were not transfused before initial danazol therapy; therefore, changes in blood counts were of limited clinical significance. The search for subgroups of patients likely to have a favorable response was unsuccessful. Side effects of danazol were limited. In addition, this study provides information on the frequency of antiplatelet antibodies and other autoantibodies in patients with MDS. Conclusions. This study does not support a positive effect of danazol in patients with MDS during long term follow-up. Anecdotal positive evolution in a few patients cannot be formally ascribed to danazol. These results should be interpreted by comparison with previous publications that report on small numbers of patients with limited follow-up. Based on these data, the authors cannot recommend the systematic use of danazol in MDS. Cancer 1994; 73:3073-80. Key words: bone marrow, hematopoiesis, myelodysplastic syndromes, smoldering leukemia, acute leukemia, androgens, danazol, thrombopenia, antiplatelet antibodies, blood transfusions.

Published
1994

34. A Phase II Lysa Study of Obinutuzumab Combined with Lenalidomide for Advanced Untretated Follicular B-Cell Lymphoma in Need of Systemic Therapy

Author

Morschhauser, Franck, primary, Salles, Gilles Andre, additional, Casasnovas, Rene-Olivier, additional, Feugier, Pierre, additional, Bouabdallah, Krimo, additional, Cartron, Guillaume, additional, Bouabdallah, Reda, additional, Nicolas-Virelizier, Emmanuelle, additional, Maerevoet, Marie, additional, Snauwaert, Sylvia, additional, Fruchart, Christophe, additional, LE Gouill, Steven, additional, Moluçon-Chabrot, Cécile, additional, Delette, Caroline, additional, Molina, Lysiane, additional, Tilly, Herve, additional, Thieblemont, Catherine, additional, Van Den Neste, Eric, additional, Bijou, Fontanet, additional, Fabiani, Bettina, additional, Haioun, Corinne, additional, and Houot, Roch, additional

Published
2018
Full Text
View/download PDF

35. Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program

Author

Manson, Guillaume, primary, Mear, Jean-Baptiste, additional, Herbaux, Charles, additional, Schiano de Collela, Jean Marc, additional, Casasnovas, Rene-Olivier, additional, Stamatoullas, Aspasia, additional, Deau-Fisher, Bénédicte, additional, Schmitt, Anna, additional, Garnier, Georges, additional, Molina, Lysiane, additional, Bouabdallah, Krimo, additional, Moles, Marie-Pierre, additional, Ghesquieres, Herv, additional, Tempescul, Adrian, additional, Dulery, Remy, additional, Nicolas-Virelizier, Emmanuelle, additional, Delmer, Alain Jacques, additional, Borel, Cecile, additional, Chauchet, Adrien, additional, Dercle, Laurent, additional, Brice, Pauline, additional, and Houot, Roch, additional

Published
2018
Full Text
View/download PDF

36. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Author

Houot, Roch, primary, Cartron, Guillaume, additional, Bijou, Fontanet, additional, de Guibert, Sophie, additional, Salles, Gilles A., additional, Fruchart, Christophe, additional, Bouabdallah, Krimo, additional, Maerevoet, Marie, additional, Feugier, Pierre, additional, Le Gouill, Steven, additional, Tilly, Hervé, additional, Casasnovas, Rene-Olivier, additional, Moluçon-Chabrot, Cécile, additional, Van Den Neste, Eric, additional, Zachee, Pierre, additional, Andre, Marc, additional, Bonnet, Christophe, additional, Haioun, Corinne, additional, Van Hoof, Achiel, additional, Van Eygen, Koen, additional, Molina, Lysiane, additional, Nicolas-Virelizier, Emmanuelle, additional, Ruminy, Philippe, additional, and Morschhauser, Franck, additional

Published
2018
Full Text
View/download PDF

37. PET Adapted Salvage Therapy for Advanced Hodgkin Lymphomas: Towards the Suppression of Positive Interim PET Unfavorable Prognosis? a Report of the Goelams Multicentric Phase 2 Trial LH2007

Author

Carras, Sylvain, primary, Dubois, Benjamin, additional, Senecal, Delphine, additional, Quittet, Philippe, additional, Vuillez, jean-Philippe, additional, peoc'H, Michel, additional, Jais, jean-Philippe, additional, Lamy, Thierry, additional, and Molina, Lysiane, additional

Published
2015
Full Text
View/download PDF

38. Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.

Author

Hu, Bei, Reagan, Patrick Michael, Sehn, Laurie Helen, Sharman, Jeff Porter, Hertzberg, Mark, Zhang, Huilai, Kim, Austin Injae, Herbaux, Charles, Molina, Lysiane, Maruyama, Dai, Smolewski, Piotr, Stenner, Frank, Craine, Veronica, Kothari, Rucha, Hirata, Jamie H., Sahin, Deniz, Sugidono, Matthew Dean Sei, Lee, Calvin, and Tilly, Herve

Published
2023
Full Text
View/download PDF

40. High Intermittent Dose of Chlorambucil Associated with Rituximab Is a Promising Treatment of Elderly Patients with Indolent Lymphoma.

Author

Andrianarison, Laingo, primary, Courby, Stephane, additional, Fabre, Blandine, additional, Molina, Lysiane, additional, Legrand, Valerie, additional, Bandelier, Brigitte Pegourie, additional, Simon, Audrey, additional, Mariette, Clara, additional, Vettier, Claire, additional, Lefebvre, Christine, additional, Garban, Frederic, additional, Bulabois, Claude Eric, additional, Thiebaut, Anne, additional, Cahn, Jean Yves, additional, and Gressin, Remy, additional

Published
2009
Full Text
View/download PDF

41. Value of Early Evaluation with FDG-PET for Follicular Lymphoma.

Author

Gressin, Remy R., primary, Vuilliez, Jean Philippe J.P., additional, Molina, Lysiane L., additional, Pegourie, Brigitte B., additional, Courby, Stephane S., additional, Garban, Frederic F., additional, Bulabois, Claude Eric C.E., additional, Orsini, Frederique F., additional, Nicolas, Emmanuelle E., additional, Makowski, Caroline C., additional, Sotto, Jean Jacques J.J., additional, and Cahn, Jean Yves J.Y., additional

Published
2005
Full Text
View/download PDF

42. Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group.

Author

Jourdan, Eric, primary, Boiron, Jean-Michel, additional, Dastugue, Nicole, additional, Vey, Norbert, additional, Marit, Gérald, additional, Rigal-Huguet, Françoise, additional, Molina, Lysiane, additional, Fegueux, Nathalie, additional, Pigneux, Arnaud, additional, Recher, Christian, additional, Rossi, Jean-François, additional, Attal, Michel, additional, Sotto, Jean-Jacques, additional, Maraninchi, Dominique, additional, Reiffers, Josy, additional, Bardou, Valérie-Jeanne, additional, and Blaise, Didier, additional

Published
2004
Full Text
View/download PDF

43. A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study.

Author

Jourdan, Eric, primary, Rigal-Huguet, Françoise, additional, Marit, Gérald, additional, Vey, Norbert, additional, Dastugue, Nicole, additional, Fegueux, Nathalie, additional, Molina, Lysiane, additional, Gastaut, Jean-Albert, additional, Legros, Laurence, additional, Zerazhi, Hacene, additional, Cailleres, Sylvie, additional, Bauduer, Frédéric, additional, Bordessoule, Dominique, additional, Attal, Michel, additional, Blaise, Didier, additional, and Pigneux, Arnaud, additional

Published
2004
Full Text
View/download PDF

45. The Use of a Sequential High Dose Recombinant Interleukin 2 Regimen After Autologous Bone Marrow Transplantation Does Not Improve the Disease Free Survival of Patients with Acute Leukemia Transplanted in First Complete Remission

Author

Blaise, Didier, primary, Attal, Michel, additional, Pico, Jose Luis, additional, Reiffers, Josy, additional, Stoppa, Anne-Marie, additional, Bellanger, Coralie, additional, Molina, Lysiane, additional, Nedellec, Gerard, additional, Vernant, Jean Paul, additional, Legros, Michel, additional, Gabus, Raul, additional, Huguet, Françoise, additional, Brandely, Maud, additional, Hercend, Thierry, additional, Olive, Daniel, additional, and Maraninchi, Dominique, additional

Published
1997
Full Text
View/download PDF

47. Oneversustwo high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.

Author

Jourdan, Eric, Rigal-Huguet, Françoise, Marit, Gerald, Vey, Norbert, Dastugue, Nicole, Fegueux, Nathalie, Molina, Lysiane, Gastaut, Jean-Albert, Legros, Laurence, Zerazhi, Hacene, Cailleres, Sylvie, Bauduer, Frédéric, Bordessoule, Dominique, Attal, Michel, Blaise, Didier, and Pigneux, Arnaud

Subjects
STEM cells, DRUG therapy, ACUTE myeloid leukemia, PATIENTS, LEUKEMIA, TRANSPLANTATION of organs, tissues, etc.
Abstract

We report on a randomized trial aimed to determine the impact of a second consolidative high-dose cytarabine-based chemotherapy (HiDAC) in patients with acute myeloid leukaemia prior to an autologous stem cell transplantation (ASCT). Patients aged 18–60 years, in complete remission (CR) received a first consolidation with daunorubicin and cytarabine at reduced dose. Patients not allocated to allogeneic transplantation received one course of HiDAC and then were randomized to receive an ASCT immediately (HiDAC 1 group) or after one more course of HiDAC (HiDAC 2 group). Out of the 437 initial patients, 351 achieved CR (80%), of those 277 (79%) were eligible for first HiDAC, and 128 (36%) were randomized (HiDAC 1: 65, HiDAC 2: 63). Overall survival, leukaemia-free survival and cumulative incidence of relapse and non-relapse deaths were 41% and 53% (P = 0·14), 39% and 48% (P = 0·12), 57% and 47% (P = 0·11), 8% and 8% (P = 0·95) for HiDAC 1 and HiDAC 2 groups, respectively. Further studies are warranted with a larger number of patients to test the place of a second course of HiDAC in this setting. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

49. [Dasatinib-induced follicular lymphoid hyperplasia, an entity to know].

Author

Phelippeau M, Lefebvre C, Jacob MC, Syrykh C, Ghelfi J, Carras S, Laurent C, Molina L, and Valmary-Degano S

Subjects
Humans, Dasatinib adverse effects, Hyperplasia chemically induced, Lymphoma, Follicular diagnosis, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphadenopathy
Abstract

Follicular lymphoid hyperplasia induced by dasatinib is an entity recently described. It is sometimes difficult to rule out the diagnostic of small B-cell lymphoma. Usually, the node is swollen, with follicular architecture conserved, composed by germinal centers with variable size and shape, with a hight number of mitoses and tingible bodies macrophages inside. Follicular lymphoid hyperplasia is isolated or associated with multiple reactive patterns. The immunohistochemical profil of germinal centers is CD20+, CD10+, BCL6+, BCL2-. Swollen node disappears in a short time after dasatinib discontinuation. Clinicians and pathologists need to be aware of this entity, so as not to avoid mistakenly suspect lymphoma when lymphadenopathy occurs in a patient with chronic myeloid leukemia treated with dasatinib., (Copyright © 2022 Elsevier Masson SAS. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results